1	BCL-6	BCL-6	_	_	_	_	_	_	_
2	and	and	_	_	_	_	_	_	_
3	the	the	_	_	_	_	_	_	_
4	molecular	molecular	_	_	_	_	_	_	_
5	pathogenesis	pathogenesis	_	_	_	_	_	_	_
6	of	of	_	_	_	_	_	_	_
7	B-cell	b-cell	_	_	_	_	_	_	_
8	lymphoma	lymphoma	_	_	_	_	_	_	_
9	.	.	_	_	_	_	_	_	_

1	The	the	_	_	_	_	_	_	_
2	results	result	_	_	_	_	_	_	_
3	presented	present	_	_	_	_	_	_	_
4	identify	identify	_	_	_	_	_	_	_
5	the	the	_	_	_	_	_	_	_
6	first	first	_	_	_	_	_	_	_
7	genetic	genetic	_	_	_	_	_	_	_
8	lesion	lesion	_	_	_	_	_	_	_
9	associated	associate	_	_	_	_	_	_	_
10	with	with	_	_	_	_	_	_	_
11	DLCL	DLCL	_	_	_	_	_	_	_
12	,	,	_	_	_	_	_	_	_
13	the	the	_	_	_	_	_	_	_
14	most	most	_	_	_	_	_	_	_
15	clinically	clinically	_	_	_	_	_	_	_
16	relevant	relevant	_	_	_	_	_	_	_
17	form	form	_	_	_	_	_	_	_
18	of	of	_	_	_	_	_	_	_
19	NHL	NHL	_	_	_	_	_	_	_
20	.	.	_	_	_	_	_	_	_

1	Although	although	_	_	_	_	_	_	_
2	no	no	_	_	_	_	_	_	_
3	proof	proof	_	_	_	_	_	_	_
4	yet	yet	_	_	_	_	_	_	_
5	exists	exist	_	_	_	_	_	_	_
6	of	of	_	_	_	_	_	_	_
7	a	a	_	_	_	_	_	_	_
8	role	role	_	_	_	_	_	_	_
9	for	for	_	_	_	_	_	_	_
10	these	these	_	_	_	_	_	_	_
11	lesions	lesion	_	_	_	_	_	_	_
12	in	in	_	_	_	_	_	_	_
13	DLCL	DLCL	_	_	_	_	_	_	_
14	pathogenesis	pathogenesis	_	_	_	_	_	_	_
15	,	,	_	_	_	_	_	_	_
16	the	the	_	_	_	_	_	_	_
17	feature	feature	_	_	_	_	_	_	_
18	of	of	_	_	_	_	_	_	_
19	the	the	_	_	_	_	_	_	_
20	BCL-6	BCL-6	_	_	_	_	_	_	_
21	gene	gene	_	_	_	_	_	_	_
22	product	product	_	_	_	_	_	_	_
23	,	,	_	_	_	_	_	_	_
24	its	its	_	_	_	_	_	_	_
25	specific	specific	_	_	_	_	_	_	_
26	pattern	pattern	_	_	_	_	_	_	_
27	of	of	_	_	_	_	_	_	_
28	expression	expression	_	_	_	_	_	_	_
29	in	in	_	_	_	_	_	_	_
30	B	B	_	_	_	_	_	_	_
31	cells	cell	_	_	_	_	_	_	_
32	,	,	_	_	_	_	_	_	_
33	and	and	_	_	_	_	_	_	_
34	the	the	_	_	_	_	_	_	_
35	clustering	clustering	_	_	_	_	_	_	_
36	of	of	_	_	_	_	_	_	_
37	lesions	lesion	_	_	_	_	_	_	_
38	disrupting	disrupt	_	_	_	_	_	_	_
39	its	its	_	_	_	_	_	_	_
40	regulatory	regulatory	_	_	_	_	_	_	_
41	domain	domain	_	_	_	_	_	_	_
42	strongly	strongly	_	_	_	_	_	_	_
43	suggest	suggest	_	_	_	_	_	_	_
44	that	that	_	_	_	_	_	_	_
45	deregulation	deregulation	_	_	_	_	_	_	_
46	of	of	_	_	_	_	_	_	_
47	BCL-6	BCL-6	_	_	_	_	_	_	_
48	expression	expression	_	_	_	_	_	_	_
49	may	may	_	_	_	_	_	_	_
50	contribute	contribute	_	_	_	_	_	_	_
51	to	to	_	_	_	_	_	_	_
52	DLCL	dlcl	_	_	_	_	_	_	_
53	development	development	_	_	_	_	_	_	_
54	.	.	_	_	_	_	_	_	_

1	A	a	_	_	_	_	_	_	_
2	more	more	_	_	_	_	_	_	_
3	precise	precise	_	_	_	_	_	_	_
4	definition	definition	_	_	_	_	_	_	_
5	of	of	_	_	_	_	_	_	_
6	the	the	_	_	_	_	_	_	_
7	role	role	_	_	_	_	_	_	_
8	of	of	_	_	_	_	_	_	_
9	BCL-6	bcl-6	_	_	_	_	_	_	_
10	in	in	_	_	_	_	_	_	_
11	normal	normal	_	_	_	_	_	_	_
12	and	and	_	_	_	_	_	_	_
13	neoplastic	neoplastic	_	_	_	_	_	_	_
14	B-cell	b-cell	_	_	_	_	_	_	_
15	development	development	_	_	_	_	_	_	_
16	is	be	_	_	_	_	_	_	_
17	the	the	_	_	_	_	_	_	_
18	goal	goal	_	_	_	_	_	_	_
19	of	of	_	_	_	_	_	_	_
20	ongoing	ongoing	_	_	_	_	_	_	_
21	study	study	_	_	_	_	_	_	_
22	of	of	_	_	_	_	_	_	_
23	transgenic	transgenic	_	_	_	_	_	_	_
24	mice	mouse	_	_	_	_	_	_	_
25	engineered	engineer	_	_	_	_	_	_	_
26	either	either	_	_	_	_	_	_	_
27	to	to	_	_	_	_	_	_	_
28	express	express	_	_	_	_	_	_	_
29	BCL-6	bcl-6	_	_	_	_	_	_	_
30	under	under	_	_	_	_	_	_	_
31	heterologous	heterologous	_	_	_	_	_	_	_
32	promoters	promoter	_	_	_	_	_	_	_
33	or	or	_	_	_	_	_	_	_
34	lacking	lack	_	_	_	_	_	_	_
35	BCL-6	bcl-6	_	_	_	_	_	_	_
36	function	function	_	_	_	_	_	_	_
37	due	due	_	_	_	_	_	_	_
38	to	to	_	_	_	_	_	_	_
39	targeted	target	_	_	_	_	_	_	_
40	deletions	deletion	_	_	_	_	_	_	_
41	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	addition	addition	_	_	_	_	_	_	_
3	to	to	_	_	_	_	_	_	_
4	contributing	contribute	_	_	_	_	_	_	_
5	to	to	_	_	_	_	_	_	_
6	the	the	_	_	_	_	_	_	_
7	understanding	understanding	_	_	_	_	_	_	_
8	of	of	_	_	_	_	_	_	_
9	DLCL	DLCL	_	_	_	_	_	_	_
10	pathogenesis	pathogenesis	_	_	_	_	_	_	_
11	,	,	_	_	_	_	_	_	_
12	the	the	_	_	_	_	_	_	_
13	identification	identification	_	_	_	_	_	_	_
14	of	of	_	_	_	_	_	_	_
15	BCL-6	bcl-6	_	_	_	_	_	_	_
16	lesions	lesion	_	_	_	_	_	_	_
17	may	may	_	_	_	_	_	_	_
18	have	have	_	_	_	_	_	_	_
19	relevant	relevant	_	_	_	_	_	_	_
20	clinical	clinical	_	_	_	_	_	_	_
21	implications	implication	_	_	_	_	_	_	_
22	.	.	_	_	_	_	_	_	_

1	DLCL	DLCL	_	_	_	_	_	_	_
2	represent	represent	_	_	_	_	_	_	_
3	a	a	_	_	_	_	_	_	_
4	heterogeneous	heterogeneous	_	_	_	_	_	_	_
5	group	group	_	_	_	_	_	_	_
6	of	of	_	_	_	_	_	_	_
7	neoplasms	neoplasm	_	_	_	_	_	_	_
8	which	which	_	_	_	_	_	_	_
9	are	be	_	_	_	_	_	_	_
10	treated	treat	_	_	_	_	_	_	_
11	homogeneously	homogeneously	_	_	_	_	_	_	_
12	despite	despite	_	_	_	_	_	_	_
13	the	the	_	_	_	_	_	_	_
14	fact	fact	_	_	_	_	_	_	_
15	that	that	_	_	_	_	_	_	_
16	only	only	_	_	_	_	_	_	_
17	50	50	_	_	_	_	_	_	_
18	%	%	_	_	_	_	_	_	_
19	of	of	_	_	_	_	_	_	_
20	patients	patient	_	_	_	_	_	_	_
21	experience	experience	_	_	_	_	_	_	_
22	long-term	long-term	_	_	_	_	_	_	_
23	disease-free	disease-free	_	_	_	_	_	_	_
24	survival	survival	_	_	_	_	_	_	_
25	(	(	_	_	_	_	_	_	_
26	Schneider	Schneider	_	_	_	_	_	_	_
27	et	et	_	_	_	_	_	_	_
28	al.	al.	_	_	_	_	_	_	_
29	1990	1990	_	_	_	_	_	_	_
30	)	)	_	_	_	_	_	_	_
31	.	.	_	_	_	_	_	_	_

1	The	the	_	_	_	_	_	_	_
2	fact	fact	_	_	_	_	_	_	_
3	that	that	_	_	_	_	_	_	_
4	BCL-6	bcl-6	_	_	_	_	_	_	_
5	rearrangements	rearrangement	_	_	_	_	_	_	_
6	identify	identify	_	_	_	_	_	_	_
7	biologically	biologically	_	_	_	_	_	_	_
8	and	and	_	_	_	_	_	_	_
9	clinically	clinically	_	_	_	_	_	_	_
10	distinct	distinct	_	_	_	_	_	_	_
11	subsets	subset	_	_	_	_	_	_	_
12	of	of	_	_	_	_	_	_	_
13	DLCL	DLCL	_	_	_	_	_	_	_
14	suggests	suggest	_	_	_	_	_	_	_
15	that	that	_	_	_	_	_	_	_
16	these	these	_	_	_	_	_	_	_
17	lesions	lesion	_	_	_	_	_	_	_
18	may	may	_	_	_	_	_	_	_
19	be	be	_	_	_	_	_	_	_
20	useful	useful	_	_	_	_	_	_	_
21	as	as	_	_	_	_	_	_	_
22	markers	marker	_	_	_	_	_	_	_
23	in	in	_	_	_	_	_	_	_
24	selection	selection	_	_	_	_	_	_	_
25	of	of	_	_	_	_	_	_	_
26	differential	differential	_	_	_	_	_	_	_
27	therapeutic	therapeutic	_	_	_	_	_	_	_
28	strategies	strategy	_	_	_	_	_	_	_
29	based	base	_	_	_	_	_	_	_
30	on	on	_	_	_	_	_	_	_
31	different	different	_	_	_	_	_	_	_
32	risk	risk	_	_	_	_	_	_	_
33	groups	group	_	_	_	_	_	_	_
34	.	.	_	_	_	_	_	_	_

1	Furthermore	furthermore	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	the	the	_	_	_	_	_	_	_
4	BCL-6	bcl-6	_	_	_	_	_	_	_
5	rearrangements	rearrangement	_	_	_	_	_	_	_
6	can	can	_	_	_	_	_	_	_
7	be	be	_	_	_	_	_	_	_
8	used	use	_	_	_	_	_	_	_
9	to	to	_	_	_	_	_	_	_
10	identify	identify	_	_	_	_	_	_	_
11	and	and	_	_	_	_	_	_	_
12	monitor	monitor	_	_	_	_	_	_	_
13	the	the	_	_	_	_	_	_	_
14	malignant	malignant	_	_	_	_	_	_	_
15	clone	clone	_	_	_	_	_	_	_
16	with	with	_	_	_	_	_	_	_
17	sensitive	sensitive	_	_	_	_	_	_	_
18	PCR-based	pcr-based	_	_	_	_	_	_	_
19	techniques	technique	_	_	_	_	_	_	_
20	.	.	_	_	_	_	_	_	_

1	Since	since	_	_	_	_	_	_	_
2	clinical	clinical	_	_	_	_	_	_	_
3	remission	remission	_	_	_	_	_	_	_
4	has	have	_	_	_	_	_	_	_
5	been	be	_	_	_	_	_	_	_
6	observed	observe	_	_	_	_	_	_	_
7	in	in	_	_	_	_	_	_	_
8	a	a	_	_	_	_	_	_	_
9	significant	significant	_	_	_	_	_	_	_
10	fraction	fraction	_	_	_	_	_	_	_
11	of	of	_	_	_	_	_	_	_
12	DLCL	DLCL	_	_	_	_	_	_	_
13	cases	case	_	_	_	_	_	_	_
14	,	,	_	_	_	_	_	_	_
15	these	these	_	_	_	_	_	_	_
16	markers	marker	_	_	_	_	_	_	_
17	may	may	_	_	_	_	_	_	_
18	serve	serve	_	_	_	_	_	_	_
19	as	as	_	_	_	_	_	_	_
20	critical	critical	_	_	_	_	_	_	_
21	tools	tool	_	_	_	_	_	_	_
22	for	for	_	_	_	_	_	_	_
23	sensitive	sensitive	_	_	_	_	_	_	_
24	monitoring	monitoring	_	_	_	_	_	_	_
25	of	of	_	_	_	_	_	_	_
26	minimal	minimal	_	_	_	_	_	_	_
27	residual	residual	_	_	_	_	_	_	_
28	disease	disease	_	_	_	_	_	_	_
29	and	and	_	_	_	_	_	_	_
30	early	early	_	_	_	_	_	_	_
31	diagnosis	diagnosis	_	_	_	_	_	_	_
32	of	of	_	_	_	_	_	_	_
33	relapse	relapse	_	_	_	_	_	_	_
34	(	(	_	_	_	_	_	_	_
35	Gribben	Gribben	_	_	_	_	_	_	_
36	et	et	_	_	_	_	_	_	_
37	al.	al.	_	_	_	_	_	_	_
38	1993	1993	_	_	_	_	_	_	_
39	)	)	_	_	_	_	_	_	_
40	.	.	_	_	_	_	_	_	_

